| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
100 mM pentasodium 2-5A solution specifically binds to the ankyrin repeat domains 2 and 4 (K0.5 = 40 pM) of RNase L, inducing its dimerization and activating the RNA cleavage function of RNase L [1]. Endogenously produced 2-5A can activate RNase L in mouse L fibroblasts infected with encephalomyocarditis virus treated with interferon, thereby inducing ribosomal RNA cleavage [1]. A 100 mM pentasodium 2-5A solution can activate RNase L through JNK and ERK-dependent pathways and induce the expression of the MIC-1 gene in mammalian cells [1]. A 100 mM pentasodium 2-5A solution can activate RNase L through the JNK-mediated pathway and induce caspase-dependent apoptosis in mammalian cells [1].
|
|---|---|
| ln Vivo |
100 mM of 2-5A pentasodium solution (endogenously produced trimer form p3(A2'p)2A; endogenously produced by IFN-induced 2-5A synthase in response to viral double-stranded RNA) can activate RNase L, thereby mediating potent antiviral activity against a variety of viral pathogens, inducing apoptosis, and triggering transcription of antiviral genes in mice [1]. Synthetic (2'-5')ApApA (100 μg-1 mg/mouse; intraperitoneal injection; once daily for 5 days or 15 times) showed dose-dependent antileukemic activity (splenomegaly inhibition rate up to 26%) and potent antiviral activity (viremia inhibition rate up to 72%, RMLV replication inhibition rate >95%) in BALB/c male mice infected with RMLV [2].
|
| Animal Protocol |
Animal/Disease Models:BALB/c (male, RMLV-induced leukemia) [2]
Doses: 100 μg/mouse (15 doses + amphotericin B); 0.5 mg/mouse (5 doses + amphotericin B); 1 mg/mouse (5 doses; 5 doses + amphotericin B; 15 doses); Route of Administration: Intraperitoneal injection; once daily for 5 consecutive days (days 1-5 post-infection); once every 3 days for a total of 15 doses (days 1-5, 8-12, and 15-19 post-infection) Experimental Results: Average spleen weight decreased by 17% (inhibition of splenomegaly), and RMLV replication inhibition rate in transformed spleen cells was >95%. Average spleen weight decreased by 26% (inhibition of splenomegaly, P < 0.05). Mean spleen weight decreased by 23% (splenomegaly suppressed, P < 0.1). Mean spleen weight decreased by 20% (splenomegaly suppressed). Mean spleen weight decreased by 17% (splenomegaly suppressed). Mean spleen weight decreased by 17% (splenomegaly suppressed), viremia was suppressed by 72% (as measured by serum reverse transcriptase activity). |
| References |
|
| Molecular Formula |
C30H35N15NA5O25P5
|
|---|---|
| Molecular Weight |
1275.50
|
| Related CAS # |
2-5A TEA; 2-5A; 65954-93-0
|
| Appearance |
Colorless to light yellow liquid
|
| SMILES |
NC1=NC=NC2=C1N=CN2[C@H]3[C@H](OP(OC[C@@H](O[C@H]([C@@H]4OP(OC[C@@H](O[C@H]([C@@H]5O)N6C=NC7=C6N=CN=C7N)[C@H]5O)(O[Na])=O)N8C=NC9=C8N=CN=C9N)[C@H]4O)(O[Na])=O)[C@H](O)[C@@H](COP(OP(OP(O)(O[Na])=O)(O[Na])=O)(O[Na])=O)O3
|
| Synonyms |
2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7840 mL | 3.9200 mL | 7.8401 mL | |
| 5 mM | 0.1568 mL | 0.7840 mL | 1.5680 mL | |
| 10 mM | 0.0784 mL | 0.3920 mL | 0.7840 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
